Plus   Neg

Stock Alert: Aclaris Therapeutics Surges 160%

Shares of Aclaris Therapeutics, Inc. (ACRS) are surging over 160% after the clinical-stage biopharmaceutical company announced positive preliminary topline data from mid-stage trial of rheumatoid arthritis treatment.

ACRS is currently trading at $15.56, up $9.68 or 164.63%, on the Nasdaq.

Aclaris announced positive preliminary topline results from a 12-week, Phase 2a clinical trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450, an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis.

ATI-450 was developed internally utilizing Aclaris' proprietary KINect drug discovery platform.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walmart Inc. has launched a nationwide drive to boost COVID-19 vaccination rates by reaching out to more residents in vulnerable communities. The retail giant will organize a series of community events at 43 locations in 18 states to administer the COVID-19 vaccine. Walmart said it plans to continue these new events over the next several weeks as vaccine allocations allow. Pfizer Inc. (PFE) and OPKO Health Inc. (OPK) announced Friday that the European Medicines Agency or EMA has validated for review the Marketing Authorization Application for somatrogon. Pfizer expects a decision from the European Commission in 2022. The company said somatrogon is a long-acting recombinant... German telecom giant Deutsche Telekom AG reported Friday strong growth in fourth-quarter profit mainly driven by T-Mobile US results following the takeover of the competitor Sprint. Looking ahead for fiscal 2021, the company projects higher adjusted EBITDA AL, a key earnings metric.
Follow RTT